PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Moclobemide - Depression
PAD Profile : Moclobemide - Depression
Keywords :
MAOIs, monoamine oxidase inhibitors, depressive illness, antidepressants, RIMA, reversible inhibitor of monamine oxidase
Brand Names Include :
Manerix
Traffic Light Status
Status 1 of 1.
Status :
Blue
Important
Formulations :
- Tablets
Important Information :
Initiation and stabilisation by specialist for a minimum of 6 months before transfer of prescribing to primary care.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartland Integrated Care System Area Prescribing Committee have agreed a BLUE (with information sheet) traffic light status for:
· Phenelzine
· Isocarboxacid
· Moclobemide
· Tranylcypromine
Specialists will initiate and prescribe a minimum of 6 months or until the patient is stable, whichever is longer, prior to transfer of care
Associated BNF Codes
04. Central Nervous System
04.03.02. Monoamine-oxidase inhibitors (maois)